The agency has asked drugmaker Lykos Therapeutics to run an additional study on the use of the psychedelic drug in patients with post-traumatic stress disorder, pushing back its next proposal by years. Wired Read More
The agency has asked drugmaker Lykos Therapeutics to run an additional study on the use of the psychedelic drug in patients with post-traumatic stress disorder, pushing back its next proposal by years.
